NeuroSave, Inc. is a revolutionary clinical-stage medical device company based in United States, founded in 2010, with a focus on preventing and treating ischemic brain injury caused by surgery, cardiac arrest, stroke or trauma. The company's innovative approach aims to rapidly deliver the benefits of therapeutic hypothermia to the brain while safeguarding the body from the adverse effects of cooling. NeuroSave therapy sets itself apart by circulating cold fluid in the aerodigestive tract and cooling the blood in the arteries traveling to the brain, resulting in rapid brain-targeted cooling.
In both animal and human trials, NeuroSave's technology has demonstrated cerebral cooling that is far faster than any available non-surgical approach, creating a significant difference between the temperature of the body's core and brain. NeuroSave's commitment to advancing medical treatment aligns with the growing importance of innovative solutions in the health care industry.
The company's last investment was a notable $1.07M Debt Financing investment on 10 June 2015. The absence of specific investors in this latest round suggests a potential opportunity for venture capital firms seeking to invest in the future of medical technology and brain injury treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $1.07M | - | 10 Jun 2015 | |
| Debt Financing | $190.00K | - | 05 Jun 2012 |
No recent news or press coverage available for NeuroSave, Inc..
We care about your data, and we'd love to use cookies make your experience better.
